HighTower Advisors LLC Sells 6,900 Shares of OPKO Health, Inc. (NASDAQ:OPK)

HighTower Advisors LLC lessened its position in shares of OPKO Health, Inc. (NASDAQ:OPK) by 14.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,991 shares of the biotechnology company’s stock after selling 6,900 shares during the period. HighTower Advisors LLC’s holdings in OPKO Health were worth $59,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Raymond James Financial Inc. bought a new position in OPKO Health in the fourth quarter valued at about $221,000. Y Intercept Hong Kong Ltd acquired a new position in shares of OPKO Health in the fourth quarter valued at approximately $102,000. Ieq Capital LLC bought a new position in OPKO Health in the 4th quarter valued at approximately $52,000. Capital Advisors Inc. OK acquired a new stake in OPKO Health during the 4th quarter worth approximately $220,000. Finally, PFG Investments LLC grew its holdings in OPKO Health by 9.4% during the 4th quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company’s stock worth $1,707,000 after acquiring an additional 99,795 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.55 on Friday. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a twelve month low of $1.15 and a twelve month high of $2.04. The company has a fifty day moving average of $1.69 and a 200-day moving average of $1.58. The firm has a market capitalization of $1.04 billion, a P/E ratio of -8.16 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, sell-side analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Wednesday, March 19th. Barrington Research reissued an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research note on Wednesday, March 12th. Finally, StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 500,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was bought at an average cost of $1.48 per share, with a total value of $740,000.00. Following the completion of the transaction, the chief executive officer now directly owns 213,036,477 shares in the company, valued at approximately $315,293,985.96. The trade was a 0.24 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders have bought 1,214,971 shares of company stock worth $1,913,692. Corporate insiders own 49.69% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.